Cargando…
Urinary kallidinogenase for the treatment of cerebral arterial stenosis
AIM: Urinary kallidinogenase (UK) has shown promise in improving cerebral perfusion. This study aimed to examine how UK affects cognitive status and serum levels of amyloid betas (Aβs) 1-40 and 1-42 in patients with cerebral arterial stenosis. METHODS: Ninety patients with cerebral arterial stenosis...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4610775/ https://www.ncbi.nlm.nih.gov/pubmed/26508834 http://dx.doi.org/10.2147/DDDT.S93150 |
_version_ | 1782395998305255424 |
---|---|
author | Zhao, Liandong Zhao, Ying Wan, Qi Zhang, Haijun |
author_facet | Zhao, Liandong Zhao, Ying Wan, Qi Zhang, Haijun |
author_sort | Zhao, Liandong |
collection | PubMed |
description | AIM: Urinary kallidinogenase (UK) has shown promise in improving cerebral perfusion. This study aimed to examine how UK affects cognitive status and serum levels of amyloid betas (Aβs) 1-40 and 1-42 in patients with cerebral arterial stenosis. METHODS: Ninety patients with cerebral arterial stenosis were enrolled, of whom 45 patients received UK + conventional treatment (UK group), and 45 patients received conventional treatment alone as control group. Cognitive status and Aβ1-40 and Aβ1-42 serum levels were determined before treatment and at 4 weeks and 8 weeks after treatment. RESULTS: At 4 weeks after treatment, cognitive status in patients treated with UK clearly improved accompanied by Aβ1-40 serum levels decreasing while there was no change of Aβ1-42. Cognitive status in patients receiving UK continued to improve, Aβ1-40 serum levels declined further as well as Aβ1-42 serum levels began to decrease dramatically at 8 weeks after treatment. CONCLUSION: UK could improve cognitive status and decrease both Aβ1-40 and Aβ1-42 serum levels to prevent ischemic cerebral injury, which represents a good option for patients with cerebral arterial stenosis. |
format | Online Article Text |
id | pubmed-4610775 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2015 |
publisher | Dove Medical Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-46107752015-10-27 Urinary kallidinogenase for the treatment of cerebral arterial stenosis Zhao, Liandong Zhao, Ying Wan, Qi Zhang, Haijun Drug Des Devel Ther Original Research AIM: Urinary kallidinogenase (UK) has shown promise in improving cerebral perfusion. This study aimed to examine how UK affects cognitive status and serum levels of amyloid betas (Aβs) 1-40 and 1-42 in patients with cerebral arterial stenosis. METHODS: Ninety patients with cerebral arterial stenosis were enrolled, of whom 45 patients received UK + conventional treatment (UK group), and 45 patients received conventional treatment alone as control group. Cognitive status and Aβ1-40 and Aβ1-42 serum levels were determined before treatment and at 4 weeks and 8 weeks after treatment. RESULTS: At 4 weeks after treatment, cognitive status in patients treated with UK clearly improved accompanied by Aβ1-40 serum levels decreasing while there was no change of Aβ1-42. Cognitive status in patients receiving UK continued to improve, Aβ1-40 serum levels declined further as well as Aβ1-42 serum levels began to decrease dramatically at 8 weeks after treatment. CONCLUSION: UK could improve cognitive status and decrease both Aβ1-40 and Aβ1-42 serum levels to prevent ischemic cerebral injury, which represents a good option for patients with cerebral arterial stenosis. Dove Medical Press 2015-10-13 /pmc/articles/PMC4610775/ /pubmed/26508834 http://dx.doi.org/10.2147/DDDT.S93150 Text en © 2015 Zhao et al. This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution – Non Commercial (unported, v3.0) License The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0/. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. |
spellingShingle | Original Research Zhao, Liandong Zhao, Ying Wan, Qi Zhang, Haijun Urinary kallidinogenase for the treatment of cerebral arterial stenosis |
title | Urinary kallidinogenase for the treatment of cerebral arterial stenosis |
title_full | Urinary kallidinogenase for the treatment of cerebral arterial stenosis |
title_fullStr | Urinary kallidinogenase for the treatment of cerebral arterial stenosis |
title_full_unstemmed | Urinary kallidinogenase for the treatment of cerebral arterial stenosis |
title_short | Urinary kallidinogenase for the treatment of cerebral arterial stenosis |
title_sort | urinary kallidinogenase for the treatment of cerebral arterial stenosis |
topic | Original Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4610775/ https://www.ncbi.nlm.nih.gov/pubmed/26508834 http://dx.doi.org/10.2147/DDDT.S93150 |
work_keys_str_mv | AT zhaoliandong urinarykallidinogenaseforthetreatmentofcerebralarterialstenosis AT zhaoying urinarykallidinogenaseforthetreatmentofcerebralarterialstenosis AT wanqi urinarykallidinogenaseforthetreatmentofcerebralarterialstenosis AT zhanghaijun urinarykallidinogenaseforthetreatmentofcerebralarterialstenosis |